N※N

Theravance, Inc.: Theravance to Report Third Quarter 2009 Financial Results on October 27, 2009

  //health-fitness.news-articles.net/content/2009/ .. r-2009-financial-results-on-october-27-2009.html
  Published in Health and Fitness on Monday, October 19th 2009 at 13:28 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

SOUTH SAN FRANCISCO, CA--(Marketwire - October 19, 2009) - Theravance, Inc. (NASDAQ: [ THRX ]) announced today that it will release financial results for the period ended September 30, 2009 after market close on Tuesday, October 27, 2009.

An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial 888-857-6930 from the U.S., or 719-457-2710 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the company's web site at [ www.theravance.com ]. To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the conference call will be available on the company's web site for 30 days through November 26, 2009. An audio replay will also be available through 11:59 p.m. Eastern Standard Time on November 3, 2009 by dialing 888-203-1112 from the U.S., or 719-457-0820 for international callers, and entering confirmation code 5942530.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. The company's key programs include: VIBATIV™ with Astellas Pharma Inc. and the Horizon program and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency toward drug discovery, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at [ www.theravance.com ].

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

VIBATIV is a trademark of Astellas Pharma Inc.